

INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock code 股份代號: 9969)

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Introduction

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, InnoCare Pharma Limited (the "**Company**") is writing to inform you that the Company has adopted electronic dissemination of future corporate communications (the "**Corporate Communications**") ^(Note1) to its shareholders (the "**Shareholders**") and will only send Corporate Communications in printed form to its shareholders upon request.

In this connection, the following arrangements will come into effect from March 1, 2024.

1. Actionable Corporate Communications (Note2)

The Company will send the Actionable Corporate Communications to its Shareholders individually in electronic form by email. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, the Company will send the Actionable Corporate Communications in printed form together with a request form for soliciting the Shareholder's functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

2. Corporate Communications (other than Actionable Corporate Communications)

The Company will make available electronically both the English and Chinese versions of all Corporate Communications on its website (<u>www.innocarepharma.com</u>) and the Stock Exchange's website (<u>www.hkexnews.hk</u>) (the "**Website Version**") in place of printed copies.

However, subject to Shareholders' approval, until the Company has amended its articles of association, which is expected to take place at the annual general meeting proposed to be convened in June 2024, a notice of publication ("**Notice of Publication**") of the Website Version of Corporate Communications, in both English and Chinese, will be sent by the Company to Shareholders by email or by post (if in the case the Company does not possess a functional email address of a Shareholder) on the publication date of the Corporate Communications.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

It is the responsibility of the Shareholders to provide email address that is functional. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, the Company will act according to the above arrangement, including, with respect to Corporate Communications, ceasing making available the Notice of Publication to Shareholders as and when allowed by the Company's then effective memorandum and articles of association. With respect to Actionable Corporate Communications, the Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

Request for Corporate Communications and Actionable Corporate Communicates in printed form

If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form to the Share Registrar, or send an email to <u>InnoCare.ecom@computershare.com.hk</u> specifying your name, address and request to receive the all Corporate Communications in printed form. Please note that such instruction shall be valid for three years starting from the receipt date of your instruction and will expire thereafter.

Details of the arrangements for (i) the dissemination of Corporate Communications and (ii) requesting a printed copy of Corporate Communications are published under the Investors section on the Company's website (<u>www.innocarepharma.com</u>).

Should you have any queries relating to this letter, please contact the Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

By order of the Board InnoCare Pharma Limited Dr. Jisong Cui Chairperson and Executive Director

March 1, 2024

Notes:

^{1.} Corporate Communications include any documents issued or to be issued by the Company, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

^{2.} Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

To: Computershare Hong Kong Investor Services Limited (The "Share Registrar") 17M Floor, Hopewell Centre 183 Queen's Road East, Wanchai, Hong Kong (Please <u>choose ONLY ONE of the options below</u>) (請從以下選項中只選擇其中一項)	1 致:	香港中央證券登記有限公司 (「股份過戶處」) 香港灣仔皇后大道東 183 號 合和中心 17M 樓
Option 1: Provide your email address for receipt of future Actionable Corporate Communications ^(Note 3) of the Company via electronic dissemination by scanning vour personalized QR code Personalized QR Code 選項1: 掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址,以接收公司通過電子方式發佈可供採取行動的未來公司通訊 ^(MEE 3) Personalized QR Code You are NOT required to return this Reply Form if you choose Option 1. 如選擇了選項1. 閣下無須交回本回條。		
Option 2: I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications ^(Note 3) of the following listed company (the "Company") via electronic dissemination 選項 2: 本人/吾等現以書面提供本人/吾等之的電子郵件地址・以確保收到以下上市公司(「公司」)通過電子方式發佈可供採取行動的未來公司通訊 ^(附註 3) Name of Securities holder(s) 證券持有人姓名: Name of the listed company 上市公司名稱: InnoCare Pharma Limited 諾誠健華醫藥有限公司		
Email address 電郵地址: (Note 3 / 附註3)		
Option 3: I/we hereby request for receipt of Corporate Communications* in printed form (Please mark "✓" in the below box if applicable) 選項 3: 本人/吾等現要求收取公司通訊 [*] 印刷版 (如適用・請在以下方格內劃上「✓」號) receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Note 5) 收取未來公司通訊 [*] 的印刷本,並已知悉本指示由收取指示日期起計一年內有效。(附註 9) Printed English version 英文印刷本 Printed Chinese version 中文印刷本		
Signature(s): ^(Note 1) 簽名: ^(附註 1)	Contact number: 聯絡電話號碼:	Date: 日期:
Notes 解註: 1. Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid. 請薄差項要 圖下之所有資料。如屬聯名股東、則本回條須由所有聯名股東聯合簽署、方為有效。 2. Any Reply Form with no signature or othervise incorrectly completed will be void. 任何回條基本有數蓄重或是如此一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個		
PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明 (i) "Personal Data" in this statement has the same meaning as "personal data" in th 本魯明中所指的" 個人資料」與香港法例第 486章 1 個人資料, 4.145 (%) (ii) Your Personal Data provided in this Reply Form will be used in connection wirelating to your holdings in the Company. Your supply of Personal Data to the and/or request as stated in this Reply Form. 圖下於本回條所提供的個人資料解析於(包括仁不限於)有關公司以電子方式 本公司可能無法處理 圖下在本回像上所述的指示及/或要求。 (iii) Your Personal Data may be disclosed or transferred by the Company to its sub to retained for such period as may be necessary for our verification and recorn 公司可能任所於期的用錢或在法例規定的情況下,將 圖下的個人資料% (iv) You have the right to request access to and/or correction of your Perss should be in writing, by mail to the Hong Kong PrivacyOfficer@computershare.com.hk. 圖下有權相握 (私屬例) 的條文查閱及/或條次 圖下的個人資料 任何語 任提出,或發送電郵至 PrivacyOfficer@computershare.com.hk *	he Personal Data (Privacy) Ordinance, Chapter 4; 例) ('《私隱條例》」) 中 '個人資料」的逆 th, including but not limited to, the Company's Company is on a voluntary basis. In case of a fai 發布公司通訊及就 閣下持有的公司證券有關的 scidiaries, the Share Registrar, and/or other comp juproves: 竊或轉移給公司的附屬公司、脫份過戶處 '及 onal Data in accordance with the provisions of the Share Registrar at 17M Floor, Ho	86 of the Laws of Hong Kong ("PDPO"). 義相同。 electronic dissemination of Corporate Communications and to liaise with you on other matters lure to provide sufficient information, the Company may not be able to process your instruction 其他事宜上與 閣下聯絡。閣下是自願向本公司提供個人資料。若閣下未能提供足夠資料。 amies or bodies for any of the stated nurposes, or when it is required to do so by law and will
Mailing Label 鄧 斎 標 籤 Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼: 37 Hong Kong 香港	Please c	ut the mailing label and stick it on an envelope to return this form to us. No postage is necessary if posted in Hong Kong, 當 閣下客回此回條時 ·請將娶客標籤剪貼於信封上 * 如在本港投寄 · 閣下無需支付鄭費或貼上郵票。

+